TICKERNERD
Menu
LSTALSTAHealthcare · Biotechnology

LSTA Stock Forecast: Lisata Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$1.55
+37.95% on the day

The 2 Wall Street analysts covering Lisata Therapeutics, Inc. hold a median 12-month price target of $4 — +158.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 59 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$14.0M
Ticker Nerd rank
59 / 100
Median analyst target
$4.00
Analysts covering
2
Total return, dividends reinvested
1W
+41.7%
1M
−31.0%
YTD
−16.9%
1Y
−37.4%
From 52W high
−69.3%
From 52W low
+56.1%
$0.99
$5.04
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

LSTA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Lisata Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
59 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
91
Accruals
83
Growth
82
Volatility
78
Momentum
54
Issuance
53
Quality
33
Value
26
Revisions
26

Size (91): Smaller than most of the companies we track.

Revisions (26): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

LSTA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LSTA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00Oct 25Jan 26Apr 26Jul 26LSTAHigh $4.00Median $4.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says2 analysts
0 Buy2 Hold0 Sell
Low $4.00Median $4.00High $4.00

The green dot is the last close — the median target sits +158.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
15 May 2026HC Wainwright & Co.DowngradeNeutral—
21 Jan 2026Brookline CapitalDowngradeHold—
21 Aug 2025HC Wainwright & Co.ReiteratesBuy—
15 July 2025Brookline CapitalMaintainsBuy—
11 Dec 2024HC Wainwright & Co.ReiteratesBuy—
21 Nov 2024HC Wainwright & Co.ReiteratesBuy—
18 Sept 2024HC Wainwright & Co.ReiteratesBuy—
13 Aug 2024HC Wainwright & Co.ReiteratesBuy—
19 July 2024HC Wainwright & Co.ReiteratesBuy—
10 July 2024HC Wainwright & Co.ReiteratesBuy—
14 June 2024HC Wainwright & Co.ReiteratesBuy—
21 May 2024HC Wainwright & Co.ReiteratesBuy—
26 Apr 2024HC Wainwright & Co.ReiteratesBuy—
25 Apr 2024HC Wainwright & Co.ReiteratesBuy—
1 Mar 2024HC Wainwright & Co.ReiteratesBuy—
4 Jan 2024HC Wainwright & Co.ReiteratesBuy—
15 Aug 2023HC Wainwright & Co.ReiteratesBuy—
25 May 2023HC Wainwright & Co.ReiteratesBuy—
31 Mar 2023HC Wainwright & Co.ReiteratesBuy—
19 Oct 2022HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LSTA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

LSTA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Lisata Therapeutics, Inc. (LSTA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.8×

Cheaper than 81% of US stocks

Price / sales
139.7×

Cheaper than 4% of US stocks

Price / book
1.7×

Cheaper than 52% of US stocks

EV / EBITDA
−0.2×

Cheaper than 62% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
−16426.0%

Higher than 1% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−101.7%

Higher than 13% of US stocks

Return on assets
−56.7%

Higher than 7% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

LSTA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
LSTALisata Therapeutics, Inc.$14.0M
59
NRSNNeurosense Therapeutics Ltd.$14.2M
3
PHIOPhio Pharmaceuticals Corp.$13.7M
18
PASGPassage Bio, Inc.$14.3M
38
ICUSeastar Medical Holding Corp.$14.8M
24
GTBPGT Biopharma, Inc.$13.0M
14
BCDABioCardia, Inc.$15.0M
40

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Lisata Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LSTA news & analysis

Lisata Therapeutics moves forward with legal action following Kuva merger termination

Proactive Investors · 4 Aug 2026neutral

Lisata Therapeutics announced it has filed a lawsuit in the Delaware Court of Chancery alleging Kuva Labs and Kuva Acquisition Corp breached the merger agreement dated March 6, 2026, following termination of the merger. Lisata said it is acting to protect stockholder interests and strengthen its financial position.

Why it matters — LSTA watchers would care because the company is taking legal action over the failed Kuva merger to protect stockholder interests amid its development of therapies for advanced solid tumors.

Lisata Therapeutics Provides Update Following Termination of Merger Agreement

GlobeNewsWire · 4 Aug 2026negative

Lisata Therapeutics announced it has terminated its merger agreement with Kuva Labs Inc. and has filed a lawsuit seeking damages for the benefit of its stockholders.

Why it matters — A terminated merger and resulting litigation could impact Lisata's strategic direction and financial resources, introducing uncertainty for shareholders.

FAQ

Frequently asked questions about LSTA stock

What is the LSTA stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Lisata Therapeutics, Inc. have a median 12-month price target of $4, with estimates ranging from $4 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LSTA stock a buy right now?

Of the 2 analysts covering Lisata Therapeutics, Inc., 0 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Lisata Therapeutics, Inc. 59 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LSTA?

As at 22 Aug 2026, Lisata Therapeutics, Inc. ranks 59 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (91 of 100).

Will LSTA stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +158.9% from the last close, and Ticker Nerd's factor model ranks Lisata Therapeutics, Inc. 59 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LSTA stock forecast for 2030?

No analyst covering Lisata Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LSTA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $4 over the next 12 months.

How has LSTA stock performed over the past year?

Lisata Therapeutics, Inc. returned -37.4% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Lisata Therapeutics, Inc. do?

Lisata Therapeutics Inc. is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for advanced solid tumors and other serious diseases.

What is the latest news on LSTA?

The most recent item we track (Proactive Investors, 4 Aug 2026): "Lisata Therapeutics moves forward with legal action following Kuva merger termination". Lisata Therapeutics announced it has filed a lawsuit in the Delaware Court of Chancery alleging Kuva Labs and Kuva Acquisition Corp breached the merger agreement dated March 6, 2026, following termination of the merger. Lisata said it is acting to protect stockholder interests and strengthen its financial position.

Company

About Lisata Therapeutics, Inc.

Lisata Therapeutics Inc. is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for advanced solid tumors and other serious diseases. Its lead investigational product, certepetide, activates a novel uptake pathway via the CendR Platform technology, enabling co-administered or tethered anti-cancer drugs to selectively target and deeply penetrate solid tumors more effectively. This platform also targets immunosuppressive cells within the tumor microenvironment to enhance immune responses and immunotherapies. The company advances a broad clinical-stage pipeline, including trials such as ASCEND in metastatic pancreatic ductal adenocarcinoma, BOLSTER in cholangiocarcinoma, CENDIFOX in pancreatic, colon, and appendiceal cancers, iLSTA in locally advanced non-resectable pancreatic ductal adenocarcinoma, and studies in glioblastoma multiforme. Lisata Therapeutics Inc. maintains strategic partnerships, including a global non-exclusive license with Catalent for certepetide in antibody-drug conjugates and an alliance with GATC Health for AI-driven drug discovery. Founded in 1980 and headquartered in Basking Ridge, New Jersey, it operates in the oncology sector, addressing unmet needs in hard-to-treat cancers.

CEO Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D. · 26 employees · United States · https://www.lisata.com